Outcomes after auto-SCT in African Americans with multiple myeloma

Bone Marrow Transplantation

Volumn 43, Issue 11, 2009, Pages 845-851

  Khaled, Y ^a   Abidi, M H ^b   Janakiraman, N ^c   Kato, K ^a   Levine, J E ^a   Reddy, P ^a   Medina, M ^a   Peres, E ^a   Hanbali, A ^c   Mineishi, S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD34 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; LACTATE DEHYDROGENASE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE EXAMINATION; BONE LESION; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHROMOSOME DELETION 13; CONTROLLED STUDY; CYTOGENETICS; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETRANSPLANTATION; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67549145155     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.401     Document Type: Article

References (28)

1. SEER database. http://seer.cancer.gov.
2. Vlajinac HD, Pekmezović TD, Adanja BBJ, Marinković JM, Kanazir MS, Suvajdzić ND et al. Case-control study of multiple myeloma with special reference to diet as risk factor. Neoplasma 2003; 50 79-83.
3. Friedman GD. Cigarette smoking, leukemia, and multiple myeloma. Ann Epidemiol 1993; 3: 425-428.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of USadults. N Engl J Med 2003; 348: 1625-1638.
5. Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed J et al The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica 2006; 91: 1410-1413.
6. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107: 904-906.
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91-97.
8. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
9. Saraf S, Chen YH, Dobogai LC, Mahmud N, Peace D, Saunthararajah Y et al. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 1099-1102.
10. Verma PS, Howard RS, Weiss BM. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol 2008; 83: 355-358.
11. Khaled Y, Kato K, Janakiraman N, Ferrara JL, Mineishi S. Early relapses do not impact survival after autologous stem cell transplantation in African Americans with multiple myeloma. Bone Marrow Transplant 2007; 39: 727-728.
12. Bladé J, Samson D, Reece D, Apperley J, Bjōrkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
13. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E et al Autologous stem cell transplantation in multiple myeloma: Improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
14. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: A single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
15. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GEG et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003; 101: 2144-2151.
16. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
17. Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759.
18. Lahuerta JJ, Martinez-Lopez J, Serna JD, Bladé J, Grande C, Alegre A et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
19. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
20. Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés FF et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61-64.
21. Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L et al Prognostic factors for survival after autologous transplantation: A single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159-164.
22. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B et al. Complete response in multiple myeloma: Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958-1966.
23. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229-234.
24. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167.
25. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
26. Stewart AK, Fonseca RR. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339-6344.
27. Rapoport BL, Falkson HC, Falkson G. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients. S Afr Med J 1991; 79: 65-67.
28. Walker R, Barlogie B, Haessler J, Tricot GG, Anaissie EE, Shaughnessy JDJD et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121-1128.